Guggenheim Raises Price Targets for Amylyx, Salesforce, Guidewire, and Autodesk

Guggenheim Securities has raised its price targets for Amylyx Pharmaceuticals, Salesforce, Guidewire Software, and Autodesk, citing positive clinical trial developments, AI integration, recurring revenue strength, and robust quarterly earnings across healthcare, enterprise software, and insurance tech sectors.